Privium Fund Management B.V. invested $36 million [1] in Denali Therapeutics after the biotechnology company received its first approval from the FDA.

This aggressive investment signals institutional confidence in Denali's ability to commercialize its drug pipeline. For biotech firms, the transition from research to FDA-approved products is a critical pivot that often attracts significant capital from hedge funds looking for growth prospects [1].

The hedge fund's interest in the company, which trades on the NASDAQ under the symbol DNLI, began earlier this month. According to an SEC filing from May 5, 2026, Privium Fund Management B.V. initially opened a stake of $5.07 million [2]. That initial purchase consisted of 254,857 shares [2].

Following the regulatory milestone, the fund significantly increased its exposure. The reported $36 million [1] investment on May 18, 2026, represents a substantial increase over the initial position taken earlier in the month [1, 2].

Denali Therapeutics is a U.S.-based company focused on developing therapies for neurodegenerative diseases. The recent FDA approval marks the first time the company has had a drug candidate cleared for the U.S. market [1].

Privium Fund Management B.V. is betting on the growth prospects of the company as it enters this new commercial phase [1]. The rapid escalation of the investment, from roughly $5 million to $36 million within two weeks, highlights the volatility and high-reward nature of biotech investing linked to regulatory decisions [1, 2].

“Privium Fund Management B.V. invested $36 million in Denali Therapeutics after the biotechnology company received its first approval from the FDA.”

The rapid increase in Privium's position suggests that institutional investors view the first FDA approval as a 'de-risking' event for Denali Therapeutics. In the biotech sector, a first approval validates a company's platform and provides a clearer path to revenue, often triggering a shift from speculative venture-style investing to growth-oriented hedge fund strategies.